Asgard Therapeutics Collaborates With Exothera to Advance AT-108 Into Clinical Trials
Wednesday, June 12, 2024
Asgard Therapeutics, a private biotech company focused on in vivo direct cell reprogramming for cancer immunotherapy, has chosen Exothera S.A. to develop the manufacturing processes and handle clinical production for its promising therapy, AT-108. Exothera, known for its advanced capabilities in nucleic acid and viral vector production, will support Asgard Therapeutics in developing the manufacturing process for AT-108. This includes developing analytical methods, producing GMP-grade materials, and handling aseptic filling.
AT-108 is a novel off-the-shelf gene therapy aimed at triggering personalized and powerful immune responses against cancer. It works by reprogramming cancer cells in the patient to transform into Type 1 Dendritic Cells (cDC1s), which are crucial for effective anti-tumor immunity. These modified cells present the patient's unique cancer antigens to the immune system, prompting targeted and comprehensive anti-cancer responses.
Exothera's extensive facilities and experience in viral vector-based biotherapeutics will play a key role in advancing AT-108 through clinical trials. Their production capabilities, among the largest in Europe (15,000 m² – 161,500 ft²), will be vital in supporting the development of this therapy.
Asgard Therapeutics, shared her enthusiasm about progressing to the process development stage and beginning CMC activities, saying, "We look forward to collaborating with the expert team at Exothera to advance our innovative AT-108 therapy towards clinical trials."
Exothera, stated, "We are proud to assist Asgard Therapeutics in bringing these innovative therapies to patients. With our extensive experience in the production of virus-based therapeutics, we are confident in our ability to support the successful progression to clinical phases."
Source: asgardthx.com
